The TestGene company has received a Registration certificate for the kit for qualitative detection of specific regions of the genomic DNA of the hepatitis B virus and RNA of the hepatitis C and D viruses in patients with suspected infection with viral hepatitis B, C and D – "HEPA-BCD-test".

The kit has no analogues of Russian production. The uniqueness of the test system "HEPA-BCD-test" is that multiplexing allows to detect 3 types of hepatitis viruses (B, C and D) at once in one test tube with high sensitivity. This is especially important because the hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain a global healthcare problem, and co-infection with hepatitis D and hepatitis B is considered the most severe form of chronic viral hepatitis due to the rapid development of liver failure or hepatocellular carcinoma.

The hepatotropy of the causative agents of viral hepatitises explains the similarity of the main clinical manifestations of the diseases despite the fact that the infections are caused by different viruses and are significantly different in their pathogenesis.

When choosing a diagnostic system, it is important to choose the most informative one which determines highly specific regions (targets) of the genomic DNA of the hepatitis B virus and RNA of the hepatitis C and D viruses. It significantly saves labor, time and material resources of the laboratory.

"HEPA-BCD-test" is used for differential diagnostics of hepatitis, monitoring the effectiveness of the treatment, prognosing the course and outcome of the disease.

The assays are performed by one-step reverse transcription – multiplex allele-specific polymerase chain reaction with real-time hybridization fluorescence detection (real-time RT-PCR). The material for the assay is peripheral blood plasma. The test system is compatible with all open-type amplifiers (with 4 detection channels).
Back to previous page